On January 4, 2017, Saji, Hideo; Kimura, Hiroyuki; Matsuda, Hirokazu; Nakanishi, Shuichi published a patent.Related Products of 175357-98-9 The title of the patent was Preparation of pyridopyrimidine derivatives as nuclear medicine diagnostic imaging agents. And the patent contained the following:
Provided is a radioactive labeled compound that can detect a secondary mutation of an epidermal growth factor receptor and which is a compound represented by formula I or a pharmaceutically acceptable salt thereof. Compounds of formula I, wherein L1 is an alkanediyl group having 1 to 5 carbon atoms or an alkenediyl carbonyl group having 3 to 8 carbon atoms; R1 is a radioactive halogen atom, or 5- to 7-membered monocyclic nitrogen-containing heterocycloalkyl that may have one substituent, R2 is a 6- to 8-membered aryl group or nitrogen-containing heteroaryl group with one substituent; R1 or R2 contains a radioactive halogen atom or a radioactive carbon atom (11C), and Y is NH or O; are claimed. Example compound II was prepared by a multistep procedure (preparation given). The invention compounds were evaluated for their tyrosine kinase inhibiting activity (some data given). The experimental process involved the reaction of 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine(cas: 175357-98-9).Related Products of 175357-98-9
The Article related to pyridopyrimidine derivative nuclear medicine imaging agent tyrosine kinase inhibitor, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Related Products of 175357-98-9
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia